AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 231 min read$LEGN

Santos Carlos E sold $50K of LEGN

Santos Carlos E (Chief Financial Officer) sold 5,430 shares of Legend Biotech Corp (LEGN) at $9.14 on 2026-09-21.

Original reporting
SEC EDGAR · Santos Carlos E
Published Sep 23, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 8:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LEGN
Neutral
medium confidence
Mentioned
$LEGN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LEGNNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

02

Market read

A routine insider sale with limited market impact.

03

What to watch

Potential upcoming corporate actions or personal liquidity needs.

Relevance 3/10Novelty 4/10Timing: filed today

Background

SEC Form 4 filings disclose insider transactions; traders monitor them for signals of insider sentiment.

Company-level read

Ticker impact

$LEGNNeutralMedium confidence
Context

CFO Santos Carlos E sold 5,430 shares of Legend Biotech for $49,630, reducing his stake to 14,246 shares.

Expected impact

Potential slight downward pressure, likely negligible.

Evidence & confidence

The sale amount is modest and typical for diversification; no material impact expected.

Market effects

Sector

No broader sector impact; insider sale is company‑specific.

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider may be reallocating capital; sale does not imply negative outlook.

Key entities

  • Company
    Legend Biotech Corp

    Biotech firm listed on NASDAQ under ticker LEGN.

  • Individual
    Santos Carlos E

    Chief Financial Officer of Legend Biotech.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LEGN insider trading history →

Related articles

OCT 2
$LEGNHighAI 8/10

Did Five Year CARVYKTI Data Just Shift Legend Biotech's (LEGN) Investment Narrative?

Legend Biotech (LEGN) reported five-year data from the CARTITUDE-2 trial, showing 50% of relapsed or refractory multiple myeloma patients alive and progression-free without maintenance after a single CARVYKTI infusion. The results strengthen CARVYKTI's clinical staying power and potential treatment positioning. The company reported a net loss of $91.5 million on $1.27 billion revenue, with analysts projecting 19.0% yearly revenue growth and a shift to positive net income by 2029.

simplywall.st3 min
SEP 25
$LEGNMedAI 8/10

Legend Biotech Reports Five-Year CARTITUDE-2 Data Showing Durable Treatment-Free Remission With CARVYKTI in Earlier-Line Multiple Myeloma

Legend Biotech (LEGN) reported five-year data from CARTITUDE-2 showing 50% of patients with earlier-line multiple myeloma remained progression-free after a single CARVYKTI infusion. The study, presented at the 2026 IMS Annual Meeting, showed a 69.2% overall survival rate, reinforcing CARVYKTI's potential for durable remission. CARVYKTI is a BCMA-directed cell therapy developed in collaboration with Janssen Biotech.

quiverquant.com2 min
AUG 25
$LEGNHighAI 8/10

Will Legend Biotech’s (LEGN) Move to Q2 Profitability Reshape Its Investment Narrative?

Legend Biotech (LEGN) reported Q2 2026 revenue of $387.5M, up from $255.1M, and net income of $33.2M, reversing a prior loss. H1 2026 revenue was $692.6M, with net loss reduced to $21.1M. The company projects $2.2B revenue and $464.7M earnings by 2029. Analysts highlight CARVYKTI's role in profitability and pipeline assets. Management changes and CARVYKTI's dominance remain key risks.

simplywall.st2 min
AUG 14
$LEGNMedAI 8/10

Legend Biotech (LEGN) Q2 2026 Earnings Call Transcript

Legend Biotech (LEGN) reported Q2 2026 results on an earnings call. Worldwide CARVYKTI net trade sales were $657M (+50% YoY), with U.S. $472M (+32%) and ex-U.S. $185M (+128%). Total revenue was $387.5M (+52%), adjusted net income $63.1M ($0.16/share), and cash $965M. Q3 gross margin guidance was lower-50% range.

aol.com6 min